Date Filed | Type | Description |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results |
05/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/08/2023 |
8-K
| Quarterly results |
04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/24/2023 |
8-K
| Quarterly results |
04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
03/29/2023 |
8-K
| Quarterly results |
03/28/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
03/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/28/2023 |
8-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 0% stake in Corvus Pharmaceuticals, Inc. |
02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/30/2023 |
SC 13G/A
| INTEGRATED CORE STRATEGIES LLC reports a 4.1% stake in CORVUS PHARMACEUTICALS, INC. |
11/03/2022 |
8-K/A
| Quarterly results |
11/03/2022 |
8-K
| Quarterly results |
11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
10/28/2022 |
8-K
| Quarterly results |
08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/08/2022 |
8-K
| Quarterly results |
06/17/2022 |
8-K
| Quarterly results |
05/05/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
05/05/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
05/05/2022 |
8-K
| Quarterly results |
04/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/10/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
03/10/2022 |
8-K
| Quarterly results |
02/14/2022 |
SC 13G/A
| Venrock Healthcare Capital Partners II, L.P. reports a 0.5% stake in Corvus Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|